medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2012, Number 2

<< Back Next >>

Evid Med Invest Salud 2012; 5 (2)

Fallopian tube carcinoma. Report Case and literature review

Flores-Romero AL, Leyva-García O, García MR, Vásquez-Ciriaco S, Navarro-Hernández Q, Valencia-Mijares NM

Language: Spanish
References: 24
Page: 59-63
PDF size: 297.79 Kb.


ABSTRACT

Primary carcinoma of the fallopian tube is considered a rare cancer, it is the least common site for the origin of a neoplasm in the female genital tract and has an incidence from 0.2 to 0.5%. We report the case of a patient diagnosed with fallopian tube carcinoma treated with optimal cytoreduction and adjuvant chemotherapy. Female, 33 years old, without a history of importance, who begins its condition with abdominal pain a year of evolution, accompanied by nausea and vomiting. Three months before admission to the hospital, shows growth of abdominal perimeter, fullness feeling immediately after food intake and pain exacerbation. She is sent to our hospital for evaluation with ultrasound, which reveals left adnexa tumor mass. Study protocol is initiated, finding in computed tomography ascites fluid, carcinomatosis and pelvic tumor, cancer antigen125 of 359 and decides further laparotomy cytoreduction. A salpinge dependent malignant tumor is found, with histopathological diagnosis of fallopian tube carcinoma and then sent to adjuvant chemotherapy. Cancer of the fallopian tube is rare, therefore, we must study patients adequately and perform a complete cytoreduction to improve their prognosis.


REFERENCES

  1. Peters WA 3rd, Andersen WA, Hopkins MP et al. Prognostic features of carcinoma of the fallopian tube. Obstet Gynecol 1988; 71: 757-762.

  2. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the United States. Gynecol Oncol 2007; 107: 392-397.

  3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008; 26: 5284-5293.

  4. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94: 1365-1372.

  5. Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76: 45-50.

  6. Brown JV 3rd, Epstein HD, Mattison JN et al. Occult fallopian tube cancer in a patient with BRCA1 breast cancer. J Minim Invasive Gynecol 2008; 15: 749-751.

  7. Cass I, Holschneider C, Datta N et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 1327-1334.

  8. Riska A, Finne P, Alfthan H et al. Past chlamydial infection is not associated with primary fallopian tube carcinoma. Eur J Cancer 2006; 42: 1835-1838.

  9. Riska A, Sund R, Pukkala E et al. Parity, tubal sterilization, hysterectomy and risk of primary fallopian tube carcinoma in Finland, 1975-2004. Int J Cancer 2007; 120: 1351-1354.

  10. Riska A, Finne P, Koskela P et al. Human papillomavirus infection and primary fallopian tube carcinoma: a seroepidemiological study. BJOG 2007; 114: 425-429.

  11. Wolfson AH, Tralins KS, Greven KM et al. Adenocarcinoma of the fallopian tube: results of a multi-institutional retrospective analysis of 72 patients. Int J Radiat Oncol Biol Phys 1998; 40: 71-76.

  12. Tamimi HK, Figge DC. Adenocarcinoma of the uterine tube: potential for lymph node metastases. Am J Obstet Gynecol 1981; 141: 132-137.

  13. Berek JS, Hacker NF. Practical gynecologic oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.

  14. Sedlis A. Carcinoma of the fallopian tube. Surg Clin North Am 1978; 58: 121-129.

  15. Semrad N, Watring W, Fu YS et al. Fallopian tube adenocarcinoma: common extraperitoneal recurrence. Gynecol Oncol 1986; 24: 230-235.

  16. Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950; 59: 58-67.

  17. Edge SB, Byrd DR, Compton CC et al. “Fallopian tube”. In: American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer; 2010: 429.

  18. Benedet JL, Bender H, Jones H 3rd et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000; 70: 209-262.

  19. Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors. Gynecol Oncol 1989; 35: 236-239.

  20. Pfeiffer P, Mogensen H, Amtrup F, Honore E. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish Cancer Registry in a five-year period. Acta Oncol 1989; 28: 7-11.

  21. Peters WA, Andersen WA, Hopkins MP. Results of chemotherapy in advanced carcinoma of the fallopian tube. Cancer 1989; 63: 836-838.

  22. Cormio G, Maneo A, Gabriele A et al. Treatment of fallopian tube carcinoma with cyclophosphamide, adriamycin, and cisplatin. Am J Clin Oncol 1997; 20: 143-145.

  23. Klein M, Rosen A, Graf A et al. Primary fallopian tube carcinoma a retrospective survey of 51 cases. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Arch Gynecol Obstet 1994; 255: 141-146.

  24. Klein M, Rosen A, Lahousen M et al. Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube. Arch Gynecol Obstet 1994; 255: 19-24.




2020     |     www.medigraphic.com